Metastatic Prostate Cancer Clinical Trial
Official title:
Evaluation of Hypnosis in Virtual Reality on the Anxiety of Patients With Metastatic Prostate Cancer Over Chemotherapy Monocentric, Comparative, Randomized, Open Study
Prostate cancer is the first cancer in men. The treatment of metastatic prostate cancer with chemotherapy is based on the intravenous administration of docetaxel chemotherapy. Symptoms of anticipatory nausea, linked to anxiety caused by the treatment, may occur. Hypnosis is already used to treat the anxiety of people with cancer and can help treat the symtoms of nausea and vomiting of women with breast cancer. The purpose of the study is to evaluate the effect of medical hypnosis in virtual reality on the anxiety of patients with metastatic prostate cancer receiving Docetaxel chemotherapy treatment in comparison with a control group.
After verifying the patient's eligibility criteria and obtaining the signed informed consent form, the patient is randomized to the arm receiving hypnosis in virtual reality or to the control arm. The study ends after the 12 courses of docetaxel or premature termination of the study. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04400656 -
PROState Pathway Embedded Comparative Trial
|
||
| Completed |
NCT03554317 -
COMbination of Bipolar Androgen Therapy and Nivolumab
|
Phase 2 | |
| Not yet recruiting |
NCT06009549 -
A Journey Into Participation Patterns Among Metastatic Prostate Cancer Patients
|
||
| Withdrawn |
NCT05771896 -
Darolutamide With Radium-223 or Placebo and the Effect on Radiological Progression-Free Survival for Patients With mCSPC
|
Phase 3 | |
| Completed |
NCT01981122 -
A Study of Sipuleucel-T With Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer
|
Phase 2 | |
| Completed |
NCT01233557 -
Biomarkers of Bone Resorption in Metastatic Prostate Cancer
|
N/A | |
| Completed |
NCT01012141 -
Docetaxel With a Phytochemical in Treating Patients With Hormone Independent Metastatic Prostate Cancer
|
Phase 2 | |
| Recruiting |
NCT04067713 -
Plasma Analysis for Response Assessment and to DIrect the manaGement of Metastatic Prostate Cancer
|
||
| Active, not recruiting |
NCT04332744 -
Enzalutamide Plus Talazoparib for the Treatment of Hormone Sensitive Prostate Cancer (ZZ-First)
|
Phase 2 | |
| Completed |
NCT04545697 -
mHealth ElectroNic COnsultation REcording (mENCORE) in Advanced Prostate Cancer
|
N/A | |
| Recruiting |
NCT04140526 -
Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT04031378 -
Single Dose Radiotherapy (SDRT) With or Without Adjuvant Systemic Therapy for Oligometastatic Prostate Cancer
|
Phase 2 | |
| Completed |
NCT02278055 -
Non-Randomized Trial Assessing Pain Efficacy With Radium-223 in Symptomatic Metastatic Castration-Resistant Prostate Cancer
|
Phase 2 | |
| Completed |
NCT04193657 -
Toward a Comprehensive Supportive Care Intervention for Older or Frail Men With mCRPC
|
||
| Completed |
NCT02260817 -
Expanded Access to Diagnostic Imaging for Staging of Recurrent Prostate Cancer
|
Phase 3 | |
| Terminated |
NCT00216060 -
Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy
|
Phase 3 | |
| Recruiting |
NCT04070209 -
Management of Oligoprogressive Castration Resistant Prostate Cancer (PCS X)
|
Phase 2 | |
| Recruiting |
NCT04925648 -
Psma Intensity Can be Altered by Androgen and Phospho-SrC Obstruction
|
Phase 2 | |
| Completed |
NCT01303705 -
Anti-OX40, Cyclophosphamide (CTX) and Radiation in Patients With Progressive Metastatic Prostate Cancer
|
Phase 1 | |
| Completed |
NCT01560923 -
Phase II Study of Sipuleucel-T and Indoximod for Patients With Refractory Metastatic Prostate Cancer
|
Phase 2 |